Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Hanauer

Showing results (101-110 of 142) with videos related to

Pageof 15
Sort By:
Cancer|November 1, 1981
Disseminated Trichosporon beigelii (cutaneum)C W Yung, S B Hanauer, D Fretzin, et al.
Hepatology (Baltimore, Md.)|January 1, 1985
Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel diseaseJ M Bengoa, S B Hanauer, M D Sitrin, et al.
Gastroenterology|December 2, 1999
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trialE D Ehrenpreis, S V Kane, L B Cohen, et al.
The American Journal of Gastroenterology|January 1, 1989
Cigarette smoking in Crohn's diseaseM D Silverstein, B A Lashner, S B Hanauer, et al.
Digestive Diseases and Sciences|March 1, 1990
Dysplasia and cancer complicating strictures in ulcerative colitisB A Lashner, B C Turner, D G Bostwick, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2010
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled studyS Schreiber, I C Lawrance, O Ø Thomsen, et al.
Alimentary Pharmacology & Therapeutics|February 22, 2002
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studiesG N J Tytgat, L Van Nueten, I Van De Velde, et al.
Diseases of the Colon and Rectum|December 1, 1995
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporinP R Fleshner, F Michelassi, M Rubin, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|December 15, 2007
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trialS B Hanauer, W J Sandborn, C Dallaire, et al.
The American Journal of Gastroenterology|November 30, 2000
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel diseaseH S Te, T D Schiano, S F Kuan, et al.
Pageof 15

Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Cancer|November 1, 1981
Disseminated Trichosporon beigelii (cutaneum)C W Yung, S B Hanauer, D Fretzin, et al.
Hepatology (Baltimore, Md.)|January 1, 1985
Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel diseaseJ M Bengoa, S B Hanauer, M D Sitrin, et al.
Gastroenterology|December 2, 1999
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trialE D Ehrenpreis, S V Kane, L B Cohen, et al.
The American Journal of Gastroenterology|January 1, 1989
Cigarette smoking in Crohn's diseaseM D Silverstein, B A Lashner, S B Hanauer, et al.
Digestive Diseases and Sciences|March 1, 1990
Dysplasia and cancer complicating strictures in ulcerative colitisB A Lashner, B C Turner, D G Bostwick, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2010
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled studyS Schreiber, I C Lawrance, O Ø Thomsen, et al.
Alimentary Pharmacology & Therapeutics|February 22, 2002
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studiesG N J Tytgat, L Van Nueten, I Van De Velde, et al.
Diseases of the Colon and Rectum|December 1, 1995
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporinP R Fleshner, F Michelassi, M Rubin, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|December 15, 2007
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trialS B Hanauer, W J Sandborn, C Dallaire, et al.
The American Journal of Gastroenterology|November 30, 2000
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel diseaseH S Te, T D Schiano, S F Kuan, et al.
Pageof 15